Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Topic
- Accountable Care Organizations
- Alternative Payment Models
- Biopharmaceutical Innovation
- Bundled Payments
- Clinical Pathways
- Decision Frameworks
- Elements of Value
- Evidence for Decision Making
- Formulary/Benefit Design
- (-) Formulary Development
- Good Practices for Evidence
- Health Care Quality Measures
- Health Spending
- Health Spend Management
- High-Deductible Health Plans
- Impact on Outcome & Spending
- Individual Treatment Effects & Personalized Access
- IRA Implementation
- Low-Value Care
- Pandemic Response
- Patient Cost Sharing
- Paying for Cures
- Policy & Regulatory Barriers
- (-) Real-World Data
- (-) Real-World Evidence
- Regulatory Barriers & Challenges
- Understanding Health Spending
- Utilization Management & Step Therapy
- Value-Based Contracts
- Value-Based Insurance Design
- (-) Value Assessment
- Value Assessment Frameworks
- Value Assessment Methods
Resource Type
Resource Type
Audience
Audience
Display Only
Showing 96 Results
Where Are They Now: Checking In With Former NPC Intern Dan Danielson
Dan Danielson, MS, currently a senior clinical manager at Premera Blue Cross, participated in NPC’s pharmaceutical internship program in 1993. Mr. Danielson chatted with us to answer a few questions…
NPC Chief Science Officer Robert Dubois to Address Value in Personalized Medicine at 13th Annual Personalized Medicine Conference
At the 13th Annual Personalized Medicine Conference, hosted by the Personalized Medicine Coalition, NPC's Dr. Robert W. Dubois will explore why health care stakeholder viewpoints on the value of a…
IVI Introduces Transparent Approach for Value Assessment
The Innovation and Value Initiative (IVI) released its first assessment of treatments for rheumatoid arthritis using its new approach toward value assessment. NPC is still evaluating IVI’s new…
When and How is Real-World Evidence Useful in Payer Decision-Making?
Research published in Value in Health from the National Pharmaceutical Council and the University of Arizona School of Pharmacy sheds more light on how real-world evidence is used in decision-making…
Real-World Evidence: Useful in the Real World of United States Payer Decision-Making? How? When? And What Studies?
Research published in Value in Health on real-world evidence provides a deeper understanding of when and how managed care organizations use RWE in decision-making, and how to increase its use.
NPC in AJPB: Guiding Practices for Patient-Centered Value Assessment
In response to growing concerns about health care costs, during the past few years, we’ve seen an increase in the development and use of value assessment frameworks. A variety of physician, payer and…
Understanding Real-World Evidence
NPC explores the benefits and challenges with the use of real-world evidence in this first article in a series on this topic.
Appropriate Value Assessment Entails A Broad Perspective Of Impact and A Comprehensive Use of Evidence
NPC Chief Science Officer and Executive Vice President Robert W. Dubois looks at recent publications that highlight the need to consider a societal perspective when assessing value and utilize real…
Information Wanted: Finding the Balance in Pharmaceutical Evidence Exchange With Payers and Providers
Payers and providers were surveyed to understand the type of health care economic information (HCEI) they desire and value in the current and future health care environment, as well as the potential…
Making Real-World Evidence “Real” for Patients
As real-world evidence (RWE) becomes more broadly used in health care, it’s important to ensure that patients understand what RWE is, determine and address the questions and concerns patients…
Value Depends on Real-World Evidence
In his latest commentary for the American Journal of Pharmacy Benefits, NPC President Dan Leonard examines the challenges with developing, analyzing, using and communicating real-world evidence in…
An Important Dialogue About Orphan Drugs
While it’s encouraging to see that the Institute for Clinical and Economic Review (ICER) began the conversation about the value of orphan drugs, treatments that are used for conditions affecting very…
NPC is Going to ISPOR’s 22nd Annual International Meeting – Are You?
NPC will be at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 22nd Annual International Meeting, held May 20-24 in Boston, to lead issue panels and workshops,…
Health Plan Use of Patient Data: From the Routine to the Transformational
As the abundance and variety of patient data elements and sources continue to grow, health plans seek opportunities to deepen insights from multiple sources of patient data to shape care delivery,…
Is Real World Evidence Used in P&T Monographs and Therapeutic Class Reviews?
Payers infrequently used real-world evidence (RWE), or information on how treatments work in the real world, to guide their medication coverage and reimbursement decisions, according to research…
Do Payers Use Real-World Evidence to Guide Their Coverage and Reimbursement Decisions?
Payers infrequently used real-world evidence (RWE), or information on how treatments work in the real world, to guide their medication coverage and reimbursement decisions, according to new research…
Value Assessment Frameworks: Are They Up To The Challenge?
In this article published on the Health Affairs Blog, NPC researchers Dr. Robert Dubois and Kimberly Westrich ask: Are value assessment frameworks ready to compare the health and economic impacts of…
The Evolution of Value Assessment
A Health Affairs Blog post by NPC Chief Science Officer Robert Dubois, MD, PhD, and Vice President for Health Services Research Kimberly Westrich, MA, identified several key considerations that could…
Comparison of Value Framework Assessments for Multiple Myeloma
In this NPC-funded study conducted by the Lewin Group, four existing value assessment frameworks were compared head to head to understand how each framework would approach the same condition,…
How Is the Multiple Sclerosis Community Engaging on Value Assessment?
NPC President Dan Leonard caught up this week for a Q&A with Lisa Skutnik, President of the MS Coalition, to discuss how the value of multiple sclerosis (MS) treatments is being assessed,…